Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer

International Journal of Pharmaceutics

Volumn 547, Issue 1-2, 2018, Pages 611-620

  Wang, Fanwen ^a   Li, Bin ^a   Fu, Pengcheng ^b   Li, Qingqing ^a   Zheng, Heng ^a   Lao, Xingzhen ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b First People's Hospital of Chenzhou   (China)

Author keywords

Cancer therapy; iRGD; Tumor target

Indexed keywords

CD8 ANTIGEN; CD86 ANTIGEN; DRUG CARRIER; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 2; ISOLEUCYLARGINYLGLYCYLASPARTIC ACID; PACLITAXEL; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1; SYNTHETIC PEPTIDE; TETRAPEPTIDE; THYMOSIN ALPHA1; TRIFLUOROETHANOL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD86 PROTEIN, HUMAN; FUSION PROTEIN; IMMUNOLOGICAL ADJUVANT; N-END CYSTEINE PEPTIDE TUMOR-HOMING PEPTIDE; OLIGOPEPTIDE; THYMOSIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B16-F10 CELL LINE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CAPILLARY DENSITY; CIRCULAR DICHROISM; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VIVO STUDY; LUNG CANCER; LUNG CARCINOMA; MELANOMA; MOUSE; NCI-H460 CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; STRUCTURE ANALYSIS; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; LUNG TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; NUDE MOUSE; T LYMPHOCYTE; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; B7-2 ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; CIRCULAR DICHROISM; FEMALE; HUMANS; IMMUNE TOLERANCE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, NUDE; OLIGOPEPTIDES; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; THYMOSIN; TRIFLUOROETHANOL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85048703607     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2018.06.041     Document Type: Article

References (58)

1. Ancell, C.D., et al. Thymosin alpha-1. Am. J. Health Syst. Pharm. 58 (2001), 879–885 quiz 886–878.
2. Andersen, M.H., et al. Cytotoxic T cells. J. Invest. Dermatol. 126 (2006), 32–41.
3. Baumann, C.A., et al. Thymosin alpha1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int. J. Immunopharmacol. 22 (2000), 1057–1066.
4. Bogler, O., Mikkelsen, T., Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J. 9 (2003), 205–213.
5. Brooks, P.C., et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994), 569–571.
6. Chen, C.Y., et al. Molecular-cloning and expression of early t-cell costimulatory molecule-1 and its characterization as B7–2 Molecule. J. Immunol. 152 (1994), 4929–4936.
7. Chen, L., Flies, D.B., Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13 (2013), 227–242.
8. Chen, R.W., et al. Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. 73 (2013), 1352–1361.
9. Chien, R.N., et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 27 (1998), 1383–1387.
10. Danielli, R., et al. Thymosin alpha1 in melanoma: from the clinical trial setting to the daily practice and beyond. Annal. N. Y. Acad. Sci. 1270 (2012), 8–12.
11. Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
12. Eliceiri, B.P., Cheresh, D.A., Adhesion events in angiogenesis. Curr. Opin. Cell Biol. 13 (2001), 563–568.
13. Elizondo-Riojas, M.A., et al. NMR structure of human thymosin alpha-1. Biochem. Biophys. Res. Commun. 416 (2011), 356–361.
14. Friedlander, M., et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270 (1995), 1500–1502.
15. Gao, D., et al. Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization. Arch. Pharm. Res. 31 (2008), 1471–1476.
16. Garaci, E., et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann. N. Y. Acad. Sci. 1269 (2012), 26–33.
17. Gasteiger, E., et al. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. 112 (1999), 531–552.
18. Giuliani, C., et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30 (2000), 778–786.
19. Goldstein, A.L., et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl. Acad. Sci. U.S.A. 74 (1977), 725–729.
20. Goldstein, A.L., Badamchian, M., Thymosins: chemistry and biological properties in health and disease. Exp. Opin. Biol. Ther. 4 (2004), 559–573.
21. Gu, G.Z., et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials 34 (2013), 5138–5148.
22. Hadden, J.W., Thymic endocrinology. Neuroimmunomodulation 840 (1998), 352–358.
23. King, R.S., Tuthill, C., Evaluation of thymosin alpha 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis. Exp. Opin. Biol. Ther. 15:Suppl 1 (2015), 41–49.
24. Lao, X., et al. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1. PLoS ONE, 8, 2013, e72242.
25. Lao, X.Z., et al. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects. Apoptosis 20 (2015), 1307–1320.
26. Li, C., et al. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int. J. Infect. Dis. 33 (2015), 90–96.
27. Maio, M., et al. Large Randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 28 (2010), 1780–1787.
28. Mandaliti, W., et al. Thymosin alpha1 interacts with exposed phosphatidylserine in membrane models and in cells and uses serum albumin as a carrier. Biochemistry 55 (2016), 1462–1472.
29. Mandaliti, W., et al. New studies about the insertion mechanism of Thymosin alpha 1 in negative regions of model membranes as starting point of the bioactivity. Amino Acids 48 (2016), 1231–1239.
30. Mandaliti, W., et al. Thymosin alpha 1 interacts with exposed phosphatidylserine in membrane models and in cells and uses serum albumin as a carrier. Biochemistry-Us 55 (2016), 1462–1472.
31. Moody, T.W., Thymosin alpha 1 as a chemopreventive agent in lung and breast cancer. Ann. N. Y. Acad. Sci. 1112 (2007), 297–304.
32. Moody, T.W., Badamchian, M., Goldstein, A.L., Thymosin alpha one prevents lung carcinogenesis. FASEB J., 12, 1998 A1457-A1457.
33. Moody, T.W., et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res. 53 (1993), 5214–5218.
34. Moody, T.W., et al. Thymosin alpha(1) inhibits mammary carcinogenesis in Fisher rats. Peptides 23 (2002), 1011–1014.
35. Nepravishta, R., et al. Thymosin alpha 1 inserts N terminus into model membranes assuming a helical conformation. Exp. Opin. Biol. Ther. 15 (2015), S71–S81.
36. Nedrow, J.R., et al. Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma. J. Nucl. Med. 58 (2017), 1560–1566.
37. Ni, C., et al. Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression. Cancer Lett. 356 (2015), 579–588.
38. Pierluigi, B., et al. Thymosin alpha 1: the regulator of regulators?. Thymosins Health Dis. 1194 (2010), 1–5.
39. Romani, L., Bistoni, F., Gaziano, R., Bozza, S., Montagnoli, C., Perruccio, K., Pitzurra, L., Bellocchio, S., Velardi, A., Rasi, G., di Francesco, P., Garaci, E., Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood 103 (2004), 4232–4239.
40. Romani, L., et al. Jack of all trades: thymosin alpha1 and its pleiotropy. Ann. N. Y. Acad. Sci. 1269 (2012), 1–6.
41. Romani, L., et al. Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108 (2006), 2265–2274.
42. Romani, L., et al. Thymosin alpha 1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat. Med., 23, 2017, 590.
43. Ruoslahti, E., Specialization of tumour vasculature. Nat. Rev. Cancer 2 (2002), 83–90.
44. Serafino, A., et al. Thymosin alpha1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages. J. Innate Immun. 6 (2014), 72–88.
45. Sha, H., et al. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J. Controll. Release 200 (2015), 188–200.
46. Shao, C., et al. Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration. Int. Immunopharmacol. 15 (2013), 646–653.
47. Sugahara, K.N., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16 (2009), 510–520.
48. Sugahara, K.N., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328 (2010), 1031–1035.
49. Tucci, M., et al. The immune escape in melanoma: role of the impaired dendritic cell function. Exp. Rev. Clin. Immunol. 10 (2014), 1395–1404.
50. Tuthill, C., et al. Thymosin alpha1 continues to show promise as an enhancer for vaccine response. Ann. N. Y. Acad. Sci. 1270 (2012), 21–27.
51. Vats, K., et al. (99m) Tc-labeled NGR-chlorambucil conjugate, (99m) Tc-HYNIC-CLB-c(NGR) for targeted chemotherapy and molecular imaging. J. Labell. Comp. Radiopharm. 60 (2017), 431–438.
52. Volk, D.E., et al. NMR structural studies of thymosin alpha1 and beta-thymosins. Annals N. Y. Acad. Sci. 1270 (2012), 73–78.
53. Wang, K., et al. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 35 (2014), 8735–8747.
54. Wolf, G.T., et al. Interleukin 2 receptor expression in patients with head and neck squamous carcinoma. Effects of thymosin alpha 1 in vitro. Arch Otolaryngol. Head Neck Surg. 115 (1989), 1345–1349.
55. Wu, J.F., et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care, 17, 2013.
56. Xiang, X.S., et al. Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis. Inflammation 37 (2014), 402–416.
57. Yang, Y.F., et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 77 (2008), 136–141.
58. You, J., et al. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J. Gastroenterol. 12 (2006), 6715–6721.